Skip to main content
. 2018 Jan 15;10(1):256–264.

Figure 1.

Figure 1

Remodelin attenuates doxorubicin resistance in BC cells. A. BC cell lines were treated with different concentrations of doxorubicin (0, 0.0625, 0.125, 0.25, 0.5, 1.0 μg/mL) and/or remodelin (0.00, 2.50, 5.0, 7.50, 10.0 μM). Cell viability was examined using the CCK-8 assay. B, C. BC cell lines were treated with doxorubicin (0, 0.0625, 0.125, 0.25, 0.5, 1.0 μg/mL) and/or remodelin (0, 0.625, 1.25, 2.5, 5, 10 μM). Cell proliferation was examined using the EDU assay; the numbers of EDU positive blotting confirmed remodelin effectively downregulated NAT10 protein expression. D. Western Bot was used to detect the interference efficiency of NAT10.